{"entity":{"type":"insider","cik":"0001563623","url":"/insider/0001563623","json_url":"/insider/0001563623.json","name":"Gengos Andrew","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":22,"n_filings":11,"first":"2013-12-18","last":"2025-06-30","span_basis":"filed_date"},"name_variants":[{"name":"Gengos Andrew","source":"filing","n_filings":11,"first_seen":"2013-12-18","last_seen":"2025-06-30"}],"transactions":[{"id":4822040,"accession":"0001562180-25-005120","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-25-005120","line_url":"/filing/0001562180-25-005120","is_derivative":false,"issuer_cik":"0001563623","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001563623","owner_cik":"0001563623","owner_name":"Gengos Andrew","owner_display_name":"Gengos Andrew","owner_url":"/insider/0001563623","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":3.9283,"price_display":"3.93","price_state":"stated","total_value":39283.0,"total_display":"39,283.00","total_whole":"39,283","shares_owned_after":25000.0,"shares_owned_after_display":"25,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-27","filed_date":"2025-06-30","scope":"insider","n_lines":2},{"id":4785228,"accession":"0001562180-25-004866","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001562180-25-004866","line_url":"/filing/0001562180-25-004866#line-3","is_derivative":false,"issuer_cik":"0001563623","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001563623","owner_cik":"0001563623","owner_name":"Gengos Andrew","owner_display_name":"Gengos Andrew","owner_url":"/insider/0001563623","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":3.9465,"price_display":"3.95","price_state":"stated","total_value":19732.5,"total_display":"19,732.50","total_whole":"19,733","shares_owned_after":15000.0,"shares_owned_after_display":"15,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-16","filed_date":"2025-06-16","scope":"insider"},{"id":4785226,"accession":"0001562180-25-004866","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-25-004866","line_url":"/filing/0001562180-25-004866","is_derivative":false,"issuer_cik":"0001563623","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001563623","owner_cik":"0001563623","owner_name":"Gengos Andrew","owner_display_name":"Gengos Andrew","owner_url":"/insider/0001563623","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":3.735,"price_display":"3.74","price_state":"stated","total_value":37350.0,"total_display":"37,350.00","total_whole":"37,350","shares_owned_after":5000.0,"shares_owned_after_display":"5,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-13","filed_date":"2025-06-16","scope":"insider","n_lines":2},{"id":2156614,"accession":"0001415889-24-022987","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-022987","line_url":"/filing/0001415889-24-022987#line-3","is_derivative":false,"issuer_cik":"0001563623","issuer_name":"Athira Pharma, Inc.","issuer_ticker":"ATHA","issuer_name_source":null,"issuer_url":"/issuer/0001563623","owner_cik":"0001563623","owner_name":"Gengos Andrew","owner_display_name":"Gengos Andrew","owner_url":"/insider/0001563623","role":"Officer (CFO and Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (CFO and Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO and Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1272.0,"shares_display":"1,272","price_per_share":0.566,"price_display":"0.57","price_state":"stated","total_value":719.952,"total_display":"719.95","total_whole":"720","shares_owned_after":97532.0,"shares_owned_after_display":"97,532","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-05","filed_date":"2024-09-05","scope":"insider"},{"id":9287234,"accession":"0001415889-24-004149","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-004149","line_url":"/filing/0001415889-24-004149#line-1","is_derivative":false,"issuer_cik":"0001563623","issuer_name":"Athira Pharma, Inc.","issuer_ticker":"ATHA","issuer_name_source":null,"issuer_url":"/issuer/0001563623","owner_cik":"0001563623","owner_name":"Gengos Andrew","owner_display_name":"Gengos Andrew","owner_url":"/insider/0001563623","role":"Officer (CFO AND CHIEF BUSINESS OFFICER)","role_mark":"O","role_mark_label":"Officer (CFO AND CHIEF BUSINESS OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO AND CHIEF BUSINESS OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1208.0,"shares_display":"1,208","price_per_share":2.91,"price_display":"2.91","price_state":"stated","total_value":3515.28,"total_display":"3,515.28","total_whole":"3,515","shares_owned_after":83804.0,"shares_owned_after_display":"83,804","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-05","filed_date":"2024-02-16","scope":"insider"},{"id":8581781,"accession":"0001209191-23-035951","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-035951","line_url":"/filing/0001209191-23-035951","is_derivative":false,"issuer_cik":"0001563623","issuer_name":"Athira Pharma, Inc.","issuer_ticker":"ATHA","issuer_name_source":null,"issuer_url":"/issuer/0001563623","owner_cik":"0001563623","owner_name":"Gengos Andrew","owner_display_name":"Gengos Andrew","owner_url":"/insider/0001563623","role":"Officer","role_mark":"O","role_mark_label":"Officer","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Below","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":3.42966718,"price_display":"3.43","price_state":"stated","total_value":51445.0077,"total_display":"51,445.01","total_whole":"51,445","shares_owned_after":80012.0,"shares_owned_after_display":"80,012","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-07","filed_date":"2023-06-09","scope":"insider","n_lines":3},{"id":8022626,"accession":"0001209191-23-034887","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-23-034887","line_url":"/filing/0001209191-23-034887","is_derivative":false,"issuer_cik":"0001563623","issuer_name":"Athira Pharma, Inc.","issuer_ticker":"ATHA","issuer_name_source":null,"issuer_url":"/issuer/0001563623","owner_cik":"0001563623","owner_name":"Gengos Andrew","owner_display_name":"Gengos Andrew","owner_url":"/insider/0001563623","role":"Officer","role_mark":"O","role_mark_label":"Officer","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Below","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":45000.0,"shares_display":"45,000","price_per_share":3.0033333333333334,"price_display":"3.00","price_state":"stated","total_value":135150.0,"total_display":"135,150.00","total_whole":"135,150","shares_owned_after":35012.0,"shares_owned_after_display":"35,012","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-05","filed_date":"2023-06-06","scope":"insider","n_lines":4},{"id":8022618,"accession":"0001209191-23-034887","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-034887","line_url":"/filing/0001209191-23-034887","is_derivative":false,"issuer_cik":"0001563623","issuer_name":"Athira Pharma, Inc.","issuer_ticker":"ATHA","issuer_name_source":null,"issuer_url":"/issuer/0001563623","owner_cik":"0001563623","owner_name":"Gengos Andrew","owner_display_name":"Gengos Andrew","owner_url":"/insider/0001563623","role":"Officer","role_mark":"O","role_mark_label":"Officer","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Below","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20012.0,"shares_display":"20,012","price_per_share":2.81941902858285,"price_display":"2.82","price_state":"stated","total_value":56422.2136,"total_display":"56,422.21","total_whole":"56,422","shares_owned_after":10012.0,"shares_owned_after_display":"10,012","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-02","filed_date":"2023-06-06","scope":"insider","n_lines":3},{"id":2981579,"accession":"0001209191-24-001153","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-24-001153","line_url":"/filing/0001209191-24-001153#line-2","is_derivative":false,"issuer_cik":"0001563623","issuer_name":"Athira Pharma, Inc.","issuer_ticker":"ATHA","issuer_name_source":null,"issuer_url":"/issuer/0001563623","owner_cik":"0001563623","owner_name":"Gengos Andrew","owner_display_name":"Gengos Andrew","owner_url":"/insider/0001563623","role":"Officer","role_mark":"O","role_mark_label":"Officer","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Below","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1208.0,"shares_display":"1,208","price_per_share":2.91,"price_display":"2.91","price_state":"stated","total_value":3515.28,"total_display":"3,515.28","total_whole":"3,515","shares_owned_after":83804.0,"shares_owned_after_display":"83,804","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-05","filed_date":"2024-01-08","scope":"insider"},{"id":8582154,"accession":"0001209191-15-083020","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-15-083020","line_url":"/filing/0001209191-15-083020#line-1","is_derivative":false,"issuer_cik":"0000822411","issuer_name":"ImmunoCellular Therapeutics, Ltd.","issuer_ticker":"IMUC","issuer_name_source":null,"issuer_url":"/issuer/0000822411","owner_cik":"0001563623","owner_name":"Gengos Andrew","owner_display_name":"Gengos Andrew","owner_url":"/insider/0001563623","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":0.435,"price_display":"0.44","price_state":"stated","total_value":4350.0,"total_display":"4,350.00","total_whole":"4,350","shares_owned_after":47000.0,"shares_owned_after_display":"47,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-11-30","filed_date":"2015-12-02","scope":"insider"},{"id":8370221,"accession":"0001209191-15-016908","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-15-016908","line_url":"/filing/0001209191-15-016908#line-1","is_derivative":false,"issuer_cik":"0000822411","issuer_name":"ImmunoCellular Therapeutics, Ltd.","issuer_ticker":"IMUC","issuer_name_source":null,"issuer_url":"/issuer/0000822411","owner_cik":"0001563623","owner_name":"Gengos Andrew","owner_display_name":"Gengos Andrew","owner_url":"/insider/0001563623","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":41333.0,"shares_display":"41,333","price_per_share":0.6,"price_display":"0.60","price_state":"stated","total_value":24799.8,"total_display":"24,799.80","total_whole":"24,800","shares_owned_after":78333.0,"shares_owned_after_display":"78,333","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-02-18","filed_date":"2015-02-20","scope":"insider"},{"id":6876602,"accession":"0001209191-14-052429","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-052429","line_url":"/filing/0001209191-14-052429#line-1","is_derivative":false,"issuer_cik":"0000822411","issuer_name":"ImmunoCellular Therapeutics, Ltd.","issuer_ticker":"IMUC","issuer_name_source":null,"issuer_url":"/issuer/0000822411","owner_cik":"0001563623","owner_name":"Gengos Andrew","owner_display_name":"Gengos Andrew","owner_url":"/insider/0001563623","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":0.8994,"price_display":"0.90","price_state":"stated","total_value":8994.0,"total_display":"8,994.00","total_whole":"8,994","shares_owned_after":37000.0,"shares_owned_after_display":"37,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-08-14","filed_date":"2014-08-14","scope":"insider"},{"id":5068917,"accession":"0001181431-13-063318","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-13-063318","line_url":"/filing/0001181431-13-063318#line-1","is_derivative":false,"issuer_cik":"0000822411","issuer_name":"ImmunoCellular Therapeutics, Ltd.","issuer_ticker":"IMUC","issuer_name_source":null,"issuer_url":"/issuer/0000822411","owner_cik":"0001563623","owner_name":"Gengos Andrew","owner_display_name":"Gengos Andrew","owner_url":"/insider/0001563623","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":27000.0,"shares_display":"27,000","price_per_share":0.7171,"price_display":"0.72","price_state":"stated","total_value":19361.7,"total_display":"19,361.70","total_whole":"19,362","shares_owned_after":27000.0,"shares_owned_after_display":"27,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-12-18","filed_date":"2013-12-18","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":22,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":19,"open_market":true},{"code":"S","label":"Open-market sale","n":3,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":22},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001831363","name":"Terns Pharmaceuticals, Inc.","url":"/issuer/0001831363","role":"Officer (Chief Financial Officer)","n_filings":2,"first_seen":"2025-06-16","last_seen":"2025-06-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001620463","name":"Athira Pharma, Inc.","url":"/issuer/0001620463","role":"Officer (CFO and Chief Business Officer)","n_filings":5,"first_seen":"2023-06-06","last_seen":"2024-09-05"},{"type":"issuer","type_label":"ISSUER","cik":"0000822411","name":"ImmunoCellular Therapeutics, Ltd.","url":"/issuer/0000822411","role":"Director, Officer (President and CEO)","n_filings":4,"first_seen":"2013-12-18","last_seen":"2015-12-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001563623","retrieved_at":"2026-08-25T16:24:56+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}